Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted radiopharmaceuticals and precision medicine for oncology and rare diseases. Headquartered in Melbourne, Australia, the company provides diagnostic PET imaging agents and therapeutic radiopharmaceutical candidates to healthcare providers across global markets including North America, Europe, and Asia-Pacific. Its commercial precision medicine portfolio features FDA-approved diagnostic agents such as Illuccix and Gozellix for prostate cancer PET imaging, alongside Pixclara for brain cancer glioma imaging. In therapeutic radiopharmaceuticals, the company advances targeted radiation candidates across urologic oncology, neurologic oncology, medullary thyroid carcinoma, and other solid tumors. Through Telix Manufacturing Solutions, the firm operates an extensive network of GMP dose production facilities, cyclotrons, and isotope processing centers ensuring reliable supply chain logistics. Telix integrates surgical solutions, advanced software, and artificial intelligence into its theranostic platform to assist nuclear medicine physicians and clinicians throughout the patient care pathway. The organization collaborates with global healthcare partners, research institutes, and clinical trial networks to bring novel molecular imaging and targeted cancer therapies to market.